PAI-I inhibition in obesity and the metabolic syndrome: A promising therapeutic strategy

Thrombosis and Haemostasis

Volumn 96, Issue 6, 2006, Pages 698-699

  Schalkwijk, Casper G ^a   Stehouwer, Coen D A ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; FIBRIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PAI 039; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PLASMINOGEN ACTIVATOR INHIBITOR 1; RIMONABANT; TIPLAXTININ; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; VERY LOW DENSITY LIPOPROTEIN RECEPTOR; INDOLEACETIC ACID DERIVATIVE;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; ANGIOGENESIS; BINDING AFFINITY; BODY FAT DISTRIBUTION; CELL DIFFERENTIATION; CELL MIGRATION; CELL SWELLING; CHOLESTEROL BLOOD LEVEL; COMPLEX FORMATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SYNTHESIS; DRUG TARGETING; EDITORIAL; FIBRINOLYSIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; LIPID TRANSPORT; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN SYNTHESIS; RECEPTOR BINDING; WEIGHT REDUCTION; ZYMOGRAPHY; ANIMAL; BLOOD; DRUG EFFECT; METABOLISM; NOTE;

ADIPOSE TISSUE; ANIMALS; ANTI-OBESITY AGENTS; FIBRINOLYSIS; HUMANS; INDOLEACETIC ACIDS; METABOLIC SYNDROME X; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 33845353424     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/06-11-0631     Document Type: Editorial

References (15)

1. Prentice AM. The emerging epidemic of obesity in developing countries. Int J Epidemiol 2006; 35: 93-9.
2. Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004; 12: 1197-211.
3. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004; 89: 463-78.
4. Alessi MC, Peiretti F, Morange P, et al. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-7.
5. Kockx M, Leenen R, Seidell J, et al. Relationship between visceral fat and PAI- 1 in overweight men and women before and after weight loss. Thromb Haemost 1999; 82: 1490-6.
6. van Dielen FM, Buurman WA, Hadfoune M, et al. Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery. J Clin Endocrinol Metab 2004; 89: 4062-8.
7. Janand-Delenne B, Chagnaud C, Raccah D, et al. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes Relat Metab Disord 1998; 22: 312-7.
8. Lijnen HR, Alessi MC, Collen D, et al. Tiplaxtinin impairs nutritionally induced obesity in mice. Thromb Haemost 2006; 96: 731-7.
9. Elokdah H, Abou-Gharbia M, Hennan JK, et al. Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. J Med Chem 2004; 47: 3491-4.
10. Crandall DL, Quinet EM, El Ayachi S, et al, Modulation of adipose tissue development by pharmacological inhibition of PAI-1. Arterioscler Thromb Vasc Biol 2006; 26: 2209-15.
11. Crandall DL, Busler DE, McHendry-Rinde B, et al. Autocrine regulation of human preadipocyte migration by plasminogen activator inhibitor-1. J Clin Endocrinol Metab 2000; 85: 2609-14.
12. Correia ML, Haynes WG. A role for plasminogen activator inhibitor-1 in obesity: from pie to PAI? Arterioscler Thromb Vasc Biol 2006; 26: 2183-5.
13. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vase Biol 2006; 26: 2200-7.
14. Lijnen HR, Alessi MC, Van Hoef B, et al. On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. J Thromb Haemost 2005; 3: 1174-9.
15. Yudkin JS, Eringa E, Stehouwer CD. "Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 2005; 365: 1817-20.